. Urine dopamine and epinephrine levels in the subcutaneous and metastatic PHEO. B6(Cg)-Tyrc-2J/J (n = 8) mice were subcutaneously injected with MTT-luciferase cells in the right lower dorsal site. B6(Cg)-Tyrc-2J/J mice (n = 8) without tumors were used as controls. (A) Urine dopamine levels in tumor-bearing mice were not significantly increased compared to those of non-tumor-bearing mice. (B) Urine epinephrine levels in mice with metastatic organ lesions were significantly higher compared to those mice with subcutaneous tumor (* p < 0.05 against subcutaneous tumor).
. Urine dopamine and epinephrine levels in the subcutaneous and metastatic PHEO. B6(Cg)-Tyrc-2J/J (n = 8) mice were subcutaneously injected with MTT-luciferase cells in the right lower dorsal site. B6(Cg)-Tyrc-2J/J mice (n = 8) without tumors were used as controls. (A) Urine dopamine levels in tumor-bearing mice were not significantly increased compared to those of non-tumor-bearing mice. (B) Urine epinephrine levels in mice with metastatic organ lesions were significantly higher compared to those mice with subcutaneous tumor (* p < 0.05 against subcutaneous tumor). Figure S2 . Tumor CD4 + , CD8 + , CD19 + , F4/80 + , and NK cells levels in the course of MBT therapy. B6(Cg)-Tyr c-2J /J mice were subcutaneously injected with MTT-luciferase cells. After tumors grew to the desired size (around 100 mm 3 ), mice were randomized into two groups (n = 24/group): (i) the group treated with MBT, (ii) the group treated with PBS. Therapy was given intratumorally on days 0, 1, 2, 8, 9, 10, 16, 17, 18, 24, 25, and 26 . Three mice from both groups were sacrificed on days 3, 7, 11, 15, and 19 of the therapy. Harvested subcutaneous tumors were used for flow cytometry analysis of tumor-infiltrating leukocytes. Three mice were sacrificed on day 0 and used as an additional controlgray triangles (no application of any compounds into the tumor). /J mice (n = 6/group for CD4 + cells depletion, n = 6/group for CD8 + depletion) were subcutaneously injected with MTT-luciferase cells. CD4 + and CD8 + subsets were depleted by administering 300 µg of depleting antibody intraperitoneally twice weekly beginning one day prior to initiation of MBTA therapy. The depletion of CD8 + and CD4 + T cells from PBMCs on day 12 was confirmed using flow cytometry.
